Salarius Pharmaceuticals, INC. (DCOY) — 10-Q Filings

10-Q Filings (6)

• Salarius Narrows Losses, Boosts Cash Post-Decoy Merger — Nov 14, 2025 Risk: high
  Salarius Pharmaceuticals, Inc. (DCOY) reported a net loss of $873,467 for the three months ended September 30, 2025, an improvement from a net loss of $972,121
• Salarius Posts Q2 Net Loss of $5.5M, Continues Equity Funding — Aug 12, 2025 Risk: high
  Salarius Pharmaceuticals, Inc. (DCOY) reported no revenue for the three and six months ended June 30, 2025, consistent with the prior year periods, indicating i
• Salarius Pharmaceuticals Files Q1 2025 10-Q — May 14, 2025 Risk: medium
  Salarius Pharmaceuticals, Inc. filed a 10-Q for the period ending March 31, 2025. The company, formerly known as Flex Pharma, Inc., is based in Houston, TX. Fin
• Salarius Pharmaceuticals Files Q3 2024 10-Q — Nov 14, 2024 Risk: medium
  Salarius Pharmaceuticals, Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly known as Flex Pharma, Inc., reported financial res
• Salarius Pharmaceuticals Files Q2 2024 10-Q — Aug 9, 2024 Risk: medium
  Salarius Pharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its busine
• Salarius Pharmaceuticals, Inc. Files 10-Q for Period Ending March 31, 2024 — May 13, 2024 Risk: medium
  Salarius Pharmaceuticals, Inc. (DCOY) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. Salarius Pharmaceuticals, Inc. filed a 10-Q report for the p

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX